On Thursday, Shares of Buffalo Wild Wings (NASDAQ:BWLD), lost -17.33% to $152.45.
Buffalo Wild Wings, Inc. (BWLD) declared recently financial results for the third quarter ended September 27, 2015. Highlights for the third quarter as compared to the same period a year ago were:
- Total revenue raised 22.0% to $455.5 million
- Company-owned restaurant sales raised 23.2% to $431.8 million
- Same-store sales raised 3.9% at company-owned restaurants and 1.2% at franchised restaurants
- Net earnings reduced 11.6% to $19.2 million from $21.8 million, and earnings per diluted share reduced 12.2% to $1.00 from $1.14
Sally Smith, President and Chief Executive Officer, commented, “During the third quarter we attained 41 franchised locations in Texas, New Mexico, and Hawaii, which comprises two restaurants under development. We sincerely thank the hundreds of Team Members across the country that were part of the successful transition to company ownership. Combined with our ongoing company-owned development and other franchise acquisitions during the last 12 months, we’ve raised our company-owned Buffalo Wild Wings locations by 24% contrast to a year ago.”
Buffalo Wild Wings, Inc. is an owner, operator, and franchisor of restaurants featuring a variety of menu items, counting its Buffalo, New York-style chicken wings. The Company operates Buffalo Wild Wings and Emerging brands (PizzaRev and Rusty Taco) restaurants, in addition to selling Buffalo Wild Wings and Rusty Taco restaurant franchises.
Shares of U.S. Bancorp (NYSE:USB), declined -0.12% to $43.01, during its last trading session.
U.S. Bancorp, declared that Kathy Rogers, vice chairman and chief financial officer and P.W. (Bill) Parker, vice chairman and chief risk officer, will present at the BancAnalysts Association of Boston Conference. The presentation will start at 8:10 a.m. EST on Thursday, November 5, 2015 in Boston and comprise information about U.S. Bancorp’s financial performance and corporate strategies.
U.S. Bancorp is a multi-state financial services holding company. The Company operates through its banking partner, U.S. Bank National Association, is engaged in the general banking business in domestic markets. The Company provides a range of financial services, counting lending and depository services, cash administration, capital markets, and trust and investment administration services. It also engages in credit card services, merchant and automated teller machines (ATM) processing, mortgage banking, insurance, brokerage and leasing.
Finally, Shares of Biogen Inc (NASDAQ:BIIB), ended its last trade with 0.01% gain, and closed at $293.72.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, declared recently that it has earned a fourth milestone payment in its partnershipwith Biogen (BIIB) related to progress in the companies’ research partnershipto identify microRNAs as biomarkers for multiple sclerosis (“MS”). To earn the milestone, Regulus’ microMarkersSM division used its robust technology platform and bioinformatics expertise to analyze the treatment effects of a Biogen relapsing MS drug on circulating microRNA profiles formerly identified by Regulus.
“Our partnership with Biogen is one example of how Regulus microMarkersSM is researching the role and potential of microRNAs as biomarkers for numerous diseases. We’re excited to have identified a promising microRNA biomarker for MS, which we believe was a critical step to understand how microRNAs may change response to drug treatment,” said Paul Grint, M.D., President and CEO of Regulus. “We’re excited to have realized the full potential of the collaboration, and through this work, we’re hopeful that Regulus’ micro Markers technology and bioinformatics expertise can improve understanding of multiple sclerosis.”
Regulus and Biogen began their partnership in August 2012 and expanded their research in August 2014 to identify potential microRNA biomarkers in MS. Under the scope of the agreements, Regulus has realized the full potential of the partnership and has earned $3.7 million in payments from Biogen. Following achievement of the final milestone, the scope of the research to be performed under the current partnership agreement has now concluded.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B.